Subtopic Deep Dive

Caveolin and Vascular Dysfunction
Research Guide

What is Caveolin and Vascular Dysfunction?

Caveolin-1 deficiency in knockout models disrupts endothelial nitric oxide synthase (eNOS) localization and activity in caveolae, leading to vascular abnormalities including atherosclerosis and pulmonary hypertension.

Caveolin-1 null mice exhibit hyperproliferative and vascular defects, with eNOS dysregulation in endothelial caveolae (Razani et al., 2001, 1144 citations). Studies show caveolin-1 directly inhibits eNOS through scaffolding domain interactions (Ju et al., 1997, 641 citations). Reciprocal regulation by Ca2+-calmodulin and caveolin modulates eNOS signaling (Michel et al., 1997, 603 citations).

Curated Papers

Key Challenges

Why It Matters

Caveolin-1 knockout mice develop pulmonary hypertension and cardiac hypertrophy, linking caveolae dysfunction to cardiovascular disease (Razani et al., 2001). Delivery of caveolin-1 scaffolding domain inhibits eNOS and reduces inflammation in vivo, suggesting therapeutic potential (Bucci et al., 2000). eNOS targeting to caveolae via palmitoylation and acylation is essential for NO signaling in vascular endothelium (García-Cardeña et al., 1996; Shaul et al., 1996). These findings inform drug targeting of caveolin-eNOS interactions in atherosclerosis.

Key Research Challenges

eNOS Dysregulation Mechanisms

Caveolin-1 directly binds and inhibits eNOS in caveolae, but precise molecular dynamics remain unclear (Ju et al., 1997). Reciprocal Ca2+-calmodulin regulation complicates therapeutic modulation (Michel et al., 1997). Knockout models show vascular abnormalities without full disease recapitulation (Razani et al., 2001).

Translating Knockout Phenotypes

Caveolin-1 null mice display hyperproliferation and vascular defects but remain viable, limiting atherosclerosis modeling (Razani et al., 2001). Scaffolding domain delivery reduces inflammation but requires tissue-specific targeting (Bucci et al., 2000). Human mutations need validation against mouse phenotypes.

Caveolae Mechanoprotection Loss

Endothelial caveolae provide mechanoprotection disrupted in caveolin-1 deficiency, contributing to vascular stiffness (Simons and Ehehalt, 2002). eNOS mislocalization from caveolae impairs NO-dependent vasodilation (Féron et al., 1996). Lipid raft alterations exacerbate dysfunction (Galbiati et al., 2001).

Essential Papers

Caveolin-1 Null Mice Are Viable but Show Evidence of Hyperproliferative and Vascular Abnormalities

Babak Razani, Jeffery A. Engelman, Xiaobo Wang et al. · 2001 · Journal of Biological Chemistry · 1.1K citations

Caveolin-1 is the principal structural protein of caveolae membranes in fibroblasts and endothelia. Recently, we have shown that the human CAV-1 gene is localized to a suspected tumor suppressor lo...

Nitric oxide synthases: which, where, how, and why?

Thomas Michel, Olivier Féron · 1997 · Journal of Clinical Investigation · 1.0K citations

Ca 2 ϩ i ], intracellular Ca 2 ϩ concentration; NO, nitric oxide; NOS, NO synthase.2.Where possible, references in support of introductory material will cite recent review articles rather than the ...

Cholesterol, lipid rafts, and disease

Kai Simons, Robert Ehehalt · 2002 · Journal of Clinical Investigation · 886 citations

Acylation Targets Endothelial Nitric-oxide Synthase to Plasmalemmal Caveolae

Philip W. Shaul, Eric J. Smart, Lisa Robinson et al. · 1996 · Journal of Biological Chemistry · 800 citations

Endothelial nitric-oxide synthase (eNOS) generates the key signaling molecule nitric oxide in response to intralumenal hormonal and mechanical stimuli. We designed studies to determine whether eNOS...

Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling.

Guillermo García‐Cardeña, Philmo Oh, J Liu et al. · 1996 · Proceedings of the National Academy of Sciences · 678 citations

The membrane association of endothelial nitric oxide synthase (eNOS) plays an important role in the biosynthesis of nitric oxide (NO) in vascular endothelium. Previously, we have shown that in cult...

Endothelial Nitric Oxide Synthase Targeting to Caveolae

Olivier Féron, Laurent Belhassen, Lester Kobzik et al. · 1996 · Journal of Biological Chemistry · 670 citations

The endothelial isoform of nitric oxide synthase (eNOS) modulates cardiac myocyte function and is expressed in the particulate subcellular fraction. We have previously shown that eNOS is targeted t...

Direct Interaction of Endothelial Nitric-oxide Synthase and Caveolin-1 Inhibits Synthase Activity

Hong Ju, Rong Zou, Virginia J. Venema et al. · 1997 · Journal of Biological Chemistry · 641 citations

Endothelial nitric-oxide synthase (eNOS) and caveolin-1 are associated within endothelial plasmalemmal caveolae. It is not known, however, whether eNOS and caveolin-1 interact directly or indirectl...

Reading Guide

Foundational Papers

Start with Razani et al. (2001) for caveolin-1 null mouse phenotypes (1144 citations), then Shaul et al. (1996) and García-Cardeña et al. (1996) for eNOS caveolae targeting mechanisms.

Recent Advances

Bucci et al. (2000) demonstrates scaffolding domain therapeutic effects; Galbiati et al. (2001) reviews lipid raft themes in vascular context.

Core Methods

Co-immunoprecipitation for protein interactions (Ju et al., 1997); peptide infusion for in vivo inhibition (Bucci et al., 2000); palmitoylation/acylation assays for eNOS localization (García-Cardeña et al., 1996; Shaul et al., 1996).

How PapersFlow Helps You Research Caveolin and Vascular Dysfunction

Discover & Search

Research Agent uses citationGraph on Razani et al. (2001) to map 1144 citing papers linking caveolin-1 knockouts to vascular defects, then exaSearch for 'caveolin-1 eNOS pulmonary hypertension' to find 50+ related studies. findSimilarPapers expands to lipid raft papers like Simons and Ehehalt (2002).

Analyze & Verify

Analysis Agent applies readPaperContent to extract eNOS-caveolin binding data from Ju et al. (1997), then verifyResponse with CoVe chain-of-verification against Razani et al. (2001) knockout phenotypes. runPythonAnalysis performs statistical comparison of citation networks; GRADE grading scores evidence strength for therapeutic claims from Bucci et al. (2000).

Synthesize & Write

Synthesis Agent detects gaps in human translation of mouse knockouts via contradiction flagging between Razani et al. (2001) and clinical data. Writing Agent uses latexEditText for figure legends on eNOS localization (Shaul et al., 1996), latexSyncCitations across 10 papers, and latexCompile for manuscript sections; exportMermaid visualizes caveolin-eNOS interaction pathways.

Use Cases

"Analyze eNOS activity data from caveolin-1 knockout studies"

Research Agent → searchPapers('caveolin-1 knockout eNOS') → Analysis Agent → runPythonAnalysis (pandas aggregation of NO levels from Razani 2001 + Ju 1997) → matplotlib plots of dysregulation stats.

"Write LaTeX review on caveolin-eNOS in atherosclerosis"

Synthesis Agent → gap detection (Razani 2001 vs recent) → Writing Agent → latexEditText (intro section) → latexSyncCitations (10 papers) → latexCompile → PDF with caveolae diagram.

"Find code for caveolin-eNOS binding simulations"

Research Agent → paperExtractUrls (Féron 1996) → paperFindGithubRepo → Code Discovery → githubRepoInspect → verified simulation scripts for palmitoylation dynamics.

Automated Workflows

Deep Research workflow scans 50+ papers from citationGraph of Razani et al. (2001), generating structured report on vascular phenotypes with GRADE scores. DeepScan applies 7-step CoVe analysis to Bucci et al. (2000) infusion studies, verifying inflammation reduction claims. Theorizer builds hypotheses on caveolin scaffolding peptides from Ju et al. (1997) interactions.

Try Doxa for Caveolin and Vascular Dysfunction Research

Frequently Asked Questions

What defines caveolin and vascular dysfunction?

Caveolin-1 knockout disrupts eNOS in endothelial caveolae, causing hyperproliferation, atherosclerosis, and hypertension (Razani et al., 2001).

What methods study caveolin-eNOS interactions?

Co-immunoprecipitation shows direct caveolin-1 inhibition of eNOS (Ju et al., 1997); scaffolding domain peptides block activity in vivo (Bucci et al., 2000).

What are key papers?

Razani et al. (2001, 1144 citations) on knockouts; Shaul et al. (1996, 800 citations) on eNOS acylation to caveolae; Michel et al. (1997, 603 citations) on Ca2+ regulation.

What open problems exist?

Translating mouse vascular phenotypes to human disease; tissue-specific caveolin restoration; mechanoprotection quantification in hypertension models.